Helicobactor Pylori: Basic Mechanisms to Clinical Cure 2002

ISBN-13: 9789048157785 / Angielski / Miękka / 2010 / 538 str.

R. H. Hunt; G. N. Tytgat

Opis

The fifth meeting in the successful series Helicobacter pylori: Basic Mechanisms to Clinical Cure took place in Maui, Hawaii, November 2002. The meeting focused on all current aspects of H. pylori research. Internationally acclaimed basic and clinical researchers explored, in depth, the novel information across the spectrum of H. pylori infection, the characteristics of the organism, the inflammatory and tissue modifying consequences, the overall impact of this infection on a global scale, and new therapeutic possibilities.
H. pylori infection, both in man and in the laboratory animal, has become a standard model to investigate fundamental problems in biology, such as microbial-host interactions, intracellular signalling, modulation of inflammation, mucosal atrophic metaplasia, and microbial resistance, to name just a few. The issues addressed in this book are grouped according to their leading theme. Topics include: the new Helicobacters, strain differences of H. pylori and their consequence on microbial-host interactions and the effects of H. pylori infection on the gastric mucosa. The role of H. pylori is explained in relation to: gastric carcinogenesis; gastroesophageal reflux disease; dyspepsia and long-term acid suppression. Eradication therapies are reviewed with respect to their global consequences and problems. The last two sections are devoted to a global update on therapeutic indications and finally on priorities for further research.
These proceedings accurately reflect the state-of-the-art presentations delivered by world experts. This latest volume will further enrich this top-class series on H. pylori infection.

Spis treści

Section I: The New Helicobacters.- 1 What are the new helicobacters?.- 2 Helicobacter hepaticus and Helicobacter bilis: proinflammatory modulators of enterohepatic disease.- 3 Epidemiology and postulated pathogenesis of liver and biliary tract pathogenic Helicobacter species.- 4 Evidence implicating Helicobacter spp. in the pathogenesis of inflammatory bowel disease.- Section II: Strain Differences of Helicobacter pylori.- 5 The hierarchy of markers of virulence and disease causation — useful or disappointing?.- 6 SHP-2 tyrosine phosphatase and the Helicobacter pylori virulence factor CagA.- 7 What is the exact role of Lewis antigens and autoantibodies in Helicobacter pylori-related disease?.- 8 Putative role of Helicobacter antigen in functional dyspepsia: a conceptual model.- 9 Acid adaptation of Helicobacter pylori.- 10 Co-migration of Helicobacter pylori and humans: the evolving story.- Section III: Helicobacter pylori and Gastritis — The Ongoing Saga.- 11 Progress in our understanding of H. pylori infection and gastritis.- 12 The role of pepsinogen assays as surrogate markers of gastritis dynamics in population studies.- 13 Multifocal Atrophic Gastritis (MAG) does not exist: new finding based on sectioning the entire stomach.- 14 Multifocal Atrophic Gastritis (MAG) is real, and important.- 15 Are there reliable non-invasive approaches to assessing gastritis for epidemiologic studies?.- 16 Animal models of gastritis: Helicobacter pylori and high-salt diet in the gerbil.- Section IV: Helicobacter pylori and Gastric Malignancy.- 17 The evolving epidemiology of Helicobacter pylori infection and gastric cancer.- 18 Virulence of Helicobacter pylori infection and gastric cancer: lessons from mouse models.- 19 The role of bacterial overgrowth in the stomach as an additional risk factor for gastritis.- 20 Role of ascorbate in gastric juice and the impact of Helicobacter pylori infection.- 21 Mechanisms of injury: the effects of Helicobacter pylori on cell cycle control.- 22 Role of interleukin-1 beta and other potential genetic markers as indicators of gastric cancer risk.- 23 Results of intervention trials in Helicobacter pylori-infected populations.- 24 Which lessons can be drawn from the study of Helicobacter pylori related MALT lymphoma?.- Section V: Helicobacter pylori and Clinical Issues.- 25 Helicobacter pylori eradication leads to gastro-oesophageal reflux disease.- 26 Helicobacter pylori eradication does not lead to gastro-oesophageal reflux disease.- 27 Helicobacter pylori eradication in non-ulcer dyspepsia: the case for.- 28 Helicobacter pylori eradication does not benefit non-ulcer dyspepsia.- 29 Helicobacter pylori and dyspepsia strategies — debate: Yes — A test-and-treat strategy is a viable option in primary care.- 30 A ‘test-and-treat’ strategy is obsolete in primary care.- 31 Helicobacter pylori should be eradicated in patients receiving long-term acid suppression.- 32 Helicobacter pylori eradication is not necessary before longterm proton pump inhibitor treatment.- 33 Helicobacter pylori and non-steroidal anti-inflammatory drugs: the debate is over.- Section VI: Ongoing Clinical Issues with Helicobacter pylori Infection.- 34 What are the global response rates to Helicobacter pylori eradication therapy?.- 35 What is the Helicobacter pylori global reinfection rate?.- 36 Is it time for quadruple therapy to be first line?.- 37 Eradication therapy should be different for dyspeptic patients compared with ulcer patients.- 38 Helicobacter pylori resistance to antibiotics: prevalence, mechanism, detection. What’s new?.- 39 Antibiotic sensitivities of Helicobacter pylori vary at different gastric mucosal sites.- 40 Can the response to eradication therapy in Helicobacter pylori infection be predicted?.- 41 What constitutes failure of H. pylori eradication therapy?.- 42 How can the current strategies for eradication therapy be improved?.- 43 Novel targets for Helicobacter pylori eradication.- 44 Helicobacter pylori management: how to improve the therapeutic confusion in practice.- 45 Ethical issues in the management of Helicobacter pylori infection.- 46 Are there geographic/regional differences in Helicobacter pylori eradication?.- Section VII: Global Consensus Update.- 47 Management of Helicobacter pylori infection — a review of the available regional and national guidelines.- 48 Asia Pacific guidelines for the management of Helicobacter pylori infection.- 49 What is the impact of the regional guidelines? China.- 50 H. pylori infection: Clinical management from a European perspective.- 51 What is the impact of the regional guidelines? South America.- 52 Guidelines for management of Helicobacter pylori infection in the Middle East.- 53 Global consensus update for managing Helicobacter pylori infection: critical issues from the United States.- 54 Guidelines in the management of Helicobacter pylori infection in Japan.- 55 A proposal for future Helicobacter pylori eradication guidelines.- Section VIII: Priorities for Future Research.- 56 Priorities for future research: microbiology.- 57 Priorities for further research in Helicobacter pylori management — the way forward.